Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah Lidagoster

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Current Oncology (Toronto, Ont.)|February 23, 2024
BCG and Alternative Therapies to BCG Therapy for Non-Muscle-Invasive Bladder CancerSarah Lidagoster, Reuben Ben-David, Benjamin De Leon, et al.
International Journal of Molecular Sciences|February 25, 2023
Kinesins Modify ERR1-Dependent Transcription Using a Conserved Nuclear Receptor Box MotifA M Pramodh Bandara Seneviratne, Sarah Lidagoster, Sofia Valbuena-Castor, et al.
European Urology Focus|September 21, 2024
Comparative Effectiveness of Bacillus Calmette-Guérin and Sequential Intravesical Gemcitabine and Docetaxel for Treatment-naïve Intermediate-risk Non-muscle-invasive Bladder CancerKaushik P Kolanukuduru, Reuben Ben-David, Sarah Lidagoster, et al.
BJU International|October 16, 2024
Undetectable pre-radical cystectomy circulating tumour DNA status predicts improved oncological outcomesReuben Ben-David, Sarah Lidagoster, Jack Geduldig, et al.
Urologic Oncology|September 14, 2024
The prognostic significance of circulating tumor DNA in patients with positive lymph node disease after robotic-assisted radical cystectomy: A contemporary analysisReuben Ben-David, Sarah Lidagoster, Jack Geduldig, et al.
World Journal of Urology|May 29, 2025
Does having an asymptomatic renal stone increase morbidity after radical cystectomy?Ziv Savin, Reuben Ben-David, Vinay Durbhakula, et al.
BJU International|January 23, 2025
Immunotherapy-based neoadjuvant treatment and complication rates after radical cystectomyReuben Ben-David, Francesco Pellegrino, Reza Mehrazin, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Current Oncology (Toronto, Ont.)|February 23, 2024
BCG and Alternative Therapies to BCG Therapy for Non-Muscle-Invasive Bladder CancerSarah Lidagoster, Reuben Ben-David, Benjamin De Leon, et al.
International Journal of Molecular Sciences|February 25, 2023
Kinesins Modify ERR1-Dependent Transcription Using a Conserved Nuclear Receptor Box MotifA M Pramodh Bandara Seneviratne, Sarah Lidagoster, Sofia Valbuena-Castor, et al.
European Urology Focus|September 21, 2024
Comparative Effectiveness of Bacillus Calmette-Guérin and Sequential Intravesical Gemcitabine and Docetaxel for Treatment-naïve Intermediate-risk Non-muscle-invasive Bladder CancerKaushik P Kolanukuduru, Reuben Ben-David, Sarah Lidagoster, et al.
BJU International|October 16, 2024
Undetectable pre-radical cystectomy circulating tumour DNA status predicts improved oncological outcomesReuben Ben-David, Sarah Lidagoster, Jack Geduldig, et al.
Urologic Oncology|September 14, 2024
The prognostic significance of circulating tumor DNA in patients with positive lymph node disease after robotic-assisted radical cystectomy: A contemporary analysisReuben Ben-David, Sarah Lidagoster, Jack Geduldig, et al.
World Journal of Urology|May 29, 2025
Does having an asymptomatic renal stone increase morbidity after radical cystectomy?Ziv Savin, Reuben Ben-David, Vinay Durbhakula, et al.
BJU International|January 23, 2025
Immunotherapy-based neoadjuvant treatment and complication rates after radical cystectomyReuben Ben-David, Francesco Pellegrino, Reza Mehrazin, et al.
Pageof 1